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Summary
 
We have generated transgenic mice that constitutively express murine interleukin (IL)-5 in the
lung epithelium. Airway expression of this cytokine resulted in a dramatic accumulation of
peribronchial eosinophils and striking pathologic changes including the expansion of bronchus-
associated lymphoid tissue (BALT), goblet cell hyperplasia, epithelial hypertrophy, and focal
collagen deposition. These changes were also accompanied by eosinophil infiltration of the air-
way lumen. In addition, transgenic animals displayed airway hyperresponsiveness to methacho-
line in the absence of aerosolized antigen challenge. These findings demonstrate that lung-specific
IL-5 expression can induce pathologic changes characteristic of asthma and may provide useful
models to evaluate the efficacy of potential respiratory disease therapies or pharmaceuticals.
 
T
 
he etiology of asthma has remained unclear despite di-
rect attempts to determine factors that lead to pulmo-
nary damage and loss of function. The underlying respira-
tory inflammation leading to variable airflow limitation and
airway hyperresponsiveness to various stimuli is often exac-
erbated by allergens (1), respiratory tract infections (2), or
environmental agents (e.g., air pollutants such as ozone or
tobacco smoke) (3). Localized cytokine and chemokine
gene expression (4), secretion of low molecular weight in-
flammatory mediators (5), and the recruitment of specific
leukocyte cell types (6) have all been shown to be critical
events. Positive correlations with the development of pa-
thology suggest that the process is pluricausal involving
several cell types and molecular signaling cascades. In addi-
tion, the complex inheritance patterns of genetic predispo-
sitions attest to the polygenic nature of the disorder (7).
Many pathophysiological manifestations of asthma are
associated with airway infiltration by eosinophils and lym-
phocytes mediated by cytokines and chemokines. Leuko-
cyte influx, in turn, has been associated with the devel-
opment of lung dysfunction even in nominal cases of
asthma (8). Indeed, the extent of infiltration generally cor-
relates with the severity of disease (8). Antigen-induced
mouse models of pulmonary allergic disease have proved
particularly informative in the genetic dissection of inflam-
matory pathways in the lung. Typically, these models in-
volve sensitization with a specific antigen (e.g., ovalbumin)
followed by airborne administration of the same antigen
(9). Sensitized mice treated with aerosolized allergen de-
velop leukocytic infiltrates of the airway lumen dominated
by CD4
 
 
 
 lymphocytes and eosinophils. These mice also
develop many of the changes pathognomonic of asthma in-
cluding airway hyperresponsiveness (AHR)
 
1
 
 and goblet cell
hyperplasia with excessive mucus production (10).
The cellular signals leading to airway inflammation, eosin-
ophil infiltration, and AHR remain obscure. Lymphocytes
and mast cells have been implicated as requirements for
AHR in antigen-challenged mouse models of asthma.
SCID mice, which lack both T and B lymphocytes, fail to
develop either an airway eosinophilia or AHR after oval-
bumin sensitization (11). The depletion of CD4
 
 
 
 lympho-
cytes either by treatment with anti-CD4 antibodies or
MHC class II gene knockout eliminated both eosinophil
airway infiltration and AHR in antigen-challenged mice
 
1
 
Abbreviations used in this paper:
 
 AHR, airway hyperresponsiveness; BAL,
bronchial alveolar lavage; BALT, bronchus-associated lymphoid tissue;
H/E, hematoxylin/eosin; mMBP, anti-murine eosinophil granule major
basic protein; Penh, enhanced pause; SPF, specific pathogen-free; WBC,
white blood cell.
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(12). In contrast, depletion of CD8
 
 
 
 T lymphocytes with
anti-CD8 antibodies had no effect on lung eosinophil infil-
tration but eliminated AHR (13, 14). However, recent
studies using 
 
 
 
2
 
-microglobulin–deficient mice demonstrated
no effects on AHR despite the loss of MHC I surface mol-
ecules and CD8
 
 
 
 cells (15). Finally, studies with mast cell–
deficient mice (W/W
 
v
 
) indicated that mast cells were not re-
quired for either eosinophil airway infiltration or AHR (16).
Collectively, the antigen sensitization and challenge
mouse models implicate T lymphocytes as a critical com-
ponent of the inflammatory response. Subsequent studies
have focused on interleukins produced by the T
 
H
 
2 subtype.
The necessity of IL-4 and T
 
H
 
2 cells was demonstrated by
the failure of IL-4–deficient mice to elicit airway eosino-
phil infiltration or AHR in response to antigen sensitization
and challenge (16). Ovalbumin sensitization and challenge
of IL-5–deficient mice showed that these animals also do
not  develop eosinophil airway infiltration or AHR (17).
These cytokine gene knockout studies using aerosolized anti-
gen challenge thus suggest that IL-4 and IL-5 are each impor-
tant components of proinflammatory cascades that ultimately
result in eosinophil airway infiltration and pathophysiologi-
cal changes characteristic of asthma.
Transgenic mice expressing either IL-4 or IL-5 have
provided little additional insights as to the role(s) of these
T
 
H
 
2 cytokines in the development of lung inflammatory
pathology. IL-4 has been expressed ectopically in several
cell and tissue types (18–20) including Clara cells of the air-
way epithelium (21). Expression of this cytokine in non-
lung cell types produces no pulmonary perturbations de-
spite constitutively high serum IL-4 levels. In contrast,
lung-specific expression of IL-4 (21) did lead to pathologic
pulmonary changes but, surprisingly, these changes were
nominal and did not correlate specifically to human disease.
Transgenic animal studies ectopically expressing IL-5 have
been limited to non-lung cell and tissue types (22–25), and
results from these reports also show that none of the ani-
mals developed abnormalities in the lung. However, in the
most recent of these studies (22), our group has shown that
some IL-5 effector functions appear to depend on cell- and
tissue-specific expression. This conclusion has potentially
important implications in light of clinical observations of
asthmatic patients showing the infiltration of the lung by
cells expressing high levels of IL-5 (for example see refer-
ence 26).
To test the hypothesis that many of the pathologies asso-
ciated with asthmatic patients result uniquely from lung-
specific expression of IL-5, we created transgenic mice that
constitutively express IL-5 in the airway lumen using a well-
characterized lung-specific regulatory element to drive ex-
pression in the epithelium of adult animals (27). We report
that the resulting transgenic mice develop pathophysiologic
changes including eosinophil invasion of peribronchial
spaces, epithelial hypertrophy, goblet cell hyperplasia, and
increased mucus production. These mice also show evi-
dence of eosinophil recruitment to the airway lumen at
levels comparable to asthmatic patients. Moreover, in the
absence of antigen-induced inflammation these mice none-
theless display AHR in response to methacholine chal-
lenge. Thus, lung-specific expression of IL-5 alone can re-
create many of the pathophysiologic conditions associated
with allergic respiratory disease.
 
Materials and Methods
 
Generation of Transgenic Mice.
 
A BamHI restriction fragment
containing a 5.5-kb IL-5 cDNA/genomic fusion gene (22) was
cloned into the BglII site of the plasmid pNNO3 (a kind gift of
R. Tizzard, Biogen, Cambridge, MA). A 2.3-kb BamHI frag-
ment containing the promoter region of the rat Clara cell secre-
tory protein CC10 (27) (a kind gift of J. Gitlin, Washington Uni-
versity School of Medicine, St. Louis, MO) was cloned into an
upstream BamHI site in the polylinker of this plasmid. This trans-
genic construct was excised from plasmid sequences by NotI di-
gestion and injected into embryos derived from a cross of F
 
1
 
(CBA/
CaJ 
 
 
 
 C57BL/6J) females and C57BL/6J males. Transgenic posi-
tive founder animals were identified from genomic Southern blots
of tail DNA. Subsequent generations of transgenic animals were
the result of backcrosses onto the inbred strain C57BL/6J. Animals
reported here were maintained in micro-isolator cages housed in
a specific pathogen-free (SPF) animal facility. The sentinel cages
within the animal colony surveyed negative for viral antibodies and
the presence of known mouse pathogens.
 
RNA Isolation and Northern Blot Analysis.
 
Total RNA was iso-
lated and formaldehyde-agarose Northern blots were performed
as described earlier (28).
 
Tissue In Situ Hybridization.
 
Paraffin sections of paraformal-
dehyde fixed lungs were subjected to in situ hybridization reac-
tions using 
 
35
 
S-labeled IL-5 antisense RNA probes as described
earlier (29).
 
Collection of Bronchial Alveolar Lavage Fluid and Blood Serum for
the Determination of IL-5 Levels.
 
Animals were injected (i.p.) with
a lethal dose of ketamine (600 mg/kg of body weight) and xyla-
zine (30 mg/kg of body weight) and placed under a stereodissect-
ing microscope. The trachea was exposed and a cannula was in-
serted and secured by sutures. The lungs were lavaged four times
with 1-ml aliquots of ice-cold PBS with 0.2% fetal calf serum.
3.6–3.8 ml of the instilled lavage fluid were routinely recovered
(no difference in recovery was noted between transgenic and
wild-type animals). The recovered bronchial alveolar lavage (BAL)
fluid was centrifuged (1,000 rpm for 10 min at 4
 
 
 
C) to remove
cells, and aliquots of the supernatant were frozen on dry ice and
stored at 
 
 
 
80
 
 
 
C until use. Peripheral blood (300–500 mm
 
3
 
) was
recovered by nicking the tail. Blood was allowed to clot at room
temperature for 30 min and serum was recovered by centrifuga-
tion (1,000 rpm for 10 min at 4
 
 
 
C), frozen on dry ice, and stored
at 
 
 
 
80
 
 
 
C until use. IL-5 and IL-4 levels were measured using
murine cytokine ELISA kits as described by the manufacturer
(Endogen, Inc., Boston, MA).
 
Hematologic Assays: Hematocrits, Cytospins and Smear Preparations,
Cell Counts and Differentials.
 
Microhematocrits were performed from
tail-derived blood. Blood films and marrow brush smears were
prepared as described previously (22). Cytospins of cells isolated
from collagenase-treated lungs or recovered BAL fluid were pre-
pared using a Shandon Cytospin 3 (Shandon Scientific LTD,
Cheshire, England). Cell differentials were performed from slides
stained with Leukostat (Fisher Diagnostics, Fisher Scientific, Pitts-
burgh, PA) or Wright’s stain. The specific identification of eosin-
ophils was confirmed by staining representative slides for the cya-
nide-resistant peroxidase contained in the secondary granule (28) 
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or differential staining with an eosinophil granule protein-specific
antisera. Total cell counts were quantified by hemocytometer and,
together with the percent cell type by differential, were used to
calculate specific cell number.
 
Tissue Histology.
 
Before resection, lungs were inflated with
0.5 ml of 10% phosphate-buffered formalin and fixed overnight at
room temperature. The fixed tissue samples were embedded into
paraffin and sections (4–6 
 
 
 
m) were prepared on TESPA-treated
slides for immunofluorescence or acid-washed slides for his-
tochemical staining.
 
Lung Cell Isolation and Differentials.
 
Cell suspensions were pre-
pared from collagenase treatment of perfused lungs as previously
described (14).
 
Airway Antigen Sensitization and Challenge.
 
Mice were sensitized
and challenged with aerosolized chicken ovalbumin as previously
described (30).
 
Immunofluorescence of Lung Sections.
 
Serial sections from for-
malin-fixed paraffin-embedded tissue were placed onto TESPA-
treated slides. The sections were deparaffinized using a xylene/
ethanol/water gradient, treated for 30 min in 0.1% trypsin, 0.1%
CaCl (pH 7.5), rinsed well in water, and blocked overnight (
 
 
 
12 h)
in PBS, 10% goat serum, 0.1% sodium azide at 4
 
 
 
C. The blocked
tissue sections were rinsed in PBS and then rabbit prebleed serum
(diluted 1:20) or an anti-murine eosinophil granule major basic
protein (mMBP) serum (diluted 1:20) was applied. After the ad-
dition of the primary antibody, the slides were incubated for 45
min at 37
 
 
 
C in a humidified chamber. The slides were washed
with PBS (3 
 
 
 
 5 min each) and blocked with 0.1% Chromotrope
2R (J.T. Baker, Phillipsburg, NJ) in PBS for 30 min at room
temperature. The sections were rinsed in 2–3 changes of PBS and
stained with a FITC-conjugated anti-rabbit IgG (diluted 1:40;
Sigma Chemical Co., St. Louis, MO) for 30 min at 37
 
 
 
C. The
slides were washed in PBS (3 
 
 
 
 5 min each) and coverslips
mounted using a mixture of 90% glycerol, 10% PBS, 0.1% 
 
p
 
-phen-
ylenediamine (Sigma).
 
Measurement of AHR.
 
Airway responsiveness was assessed by
inducing airflow obstruction with a methacholine aerosol using
a noninvasive method (31). This procedure estimates total pul-
monary airflow in mice (i.e., the sum of the airflows in the up-
per and lower respiratory tracts). Minute volume, tidal volume,
breathing frequency, and enhanced pause (Penh) were obtained
from conscious mice placed in a whole body plethysmograph
(model PLY 3115; Buxco Electronics Inc., Troy, NY). Mice were
unrestrained and tolerated repetitive measurements with this sys-
tem. Chamber pressure was measured with a transducer (model
TRD 5700) connected to preamplifier modules (model CHA
0150) and analyzed by System XA software (model SFT 1810).
The chamber pressure was used as a measure of the difference be-
tween thoracic expansion (or contraction) and air volume re-
moved from (or added to) the chamber during inspiration (or ex-
piration). The differential of this function with respect to time
produced a pseudo-flow value that is proportional to the differ-
ence between the rate of change of the thoracic volume and nasal
flow. Mice were placed in each chamber for 2 min and pulmo-
nary airflow obstruction was assessed by measuring Penh using
the following formula according to the manufacturer’s recom-
mendations: Penh 
 
 
 
 ([Te/0.3RT] 
 
 
 
 1) 
 
 
 
 (2PEF/3PIF), where
Penh 
 
 
 
 enhanced pause (dimensionless), Te 
 
 
 
 expiratory time
(s), RT 
 
 
 
 relaxation time (s), PEF 
 
 
 
 peak expiratory flow (ml/s),
and PIF 
 
 
 
 peak inspiratory flow (ml/s). The breathing pattern
was collected for 2 min and an average of each variable was de-
rived from 30 breaths (or 30 s, whichever occurred first). The
peak Penh value was recorded. Measurements of methacholine re-
sponsiveness were obtained by exposing mice for 1 min to saline,
followed by incremental doses (2.5–320 mg/ml) of aerosolized
methacholine (model CN-25 Collision MRE type nebulizer;
BGI, Inc., Waltham, MA) and monitoring the breathing pattern
for 2–3 min after challenge. Dose-response data were plotted and
the methacholine dose sufficient to double Penh (ED
 
200
 
) was de-
rived by log-linear interpolation. This procedure was completed
within 60 min.
 
Results
 
The Generation of Transgenic Mice Constitutively Expressing
IL-5 in the Lung Epithelium.
 
Transgenic mice expressing
IL-5 in the lung epithelium were created using the pro-
moter of the rat CC10 gene (27) and a previously described
cDNA/genomic fusion of IL-5 (22). Three independent
lines (NJ.1659, NJ.1723, NJ.1726) were initially character-
ized with respect to transgene copy number, peripheral
blood cellularity, and lung histology. All three lines of mice
had elevated white blood cell counts, including a peripheral
eosinophilia, and increases in the peribronchial cellularity
of the lung. Transgene copy number varied in each line
(NJ.1659 [1], NJ.1723 [10], NJ.1726 [15]) and generally
correlated with the extent of the observed pathologies. On
this basis, the NJ.1726 transgenic line of mice was chosen
for further study of the pathophysiologic effects of express-
ing IL-5 in the lung epithelium.
NJ.1726 mice were backcrossed to C57BL/6J (
 
 
 
/
 
 
 
) for
a minimum of four generations. All data reported are de-
rived from mice 3–8 mo of age. The transgenic animals had
live births and numbers of weaned offspring comparable to
(
 
 
 
/
 
 
 
) mice. In addition, the transgene was inherited
equally among male and female pups, indicating an autoso-
mal insertion. The apparent morbidity and life expectancy
Figure 1. Lung-specific IL-5 gene expression. Northern blot of ( / )
and NJ.1726 (Tg) tissue RNA probed with a random-primed 32P-labeled
IL-5 cDNA. Each lane contains 15  g of total RNA. Lane 1, bone mar-
row; lane 2, liver; lane 3, lung; lane 4, spleen. A photograph of the 18S
small ribosomal subunit stained with ethidium bromide is shown to verify
the presence of RNA in each lane. 
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of NJ.1726 mice were unchanged relative to transgene-
negative littermates. Northern blot analysis showed that ex-
pression of IL-5 in transgenic animals was limited to the
lung and was not detectable in any of the wild-type tissues
examined (Fig. 1). Furthermore, in situ hybridization of
adult NJ.1726 lungs shows that principle locations of IL-5
expression included Clara cells of the larger airways (data
not shown) and the proximal portion of the pulmonary
acinus (i.e., the transitional zone between the conducting
airways and the gas exchange areas) as well as cells whose
histological characteristics, number, and location suggest
that they are alveolar epithelial type II cells (Fig. 2). This
expression was found throughout the lung and is consistent
with the expression pattern of the rat CC10 gene in adult
rat lungs (32).
IL-5 levels in the BAL fluid and serum were assessed by
ELISA (Table 1). The (
 
 
 
/
 
 
 
) level of IL-5 in both com-
partments was at or below the level of detection (
 
 
 
5pg/ml).
In contrast, IL-5 levels in BAL fluid of NJ.1726 mice were
dramatically elevated (269 ng/total lavage). An apparent con-
sequence of airway expression at these high levels was dis-
placement of IL-5 into the vasculature such that serum IL-5
was 
 
 
 
1,700 pg/ml. IL-4 was not detectable (i.e., 
 
 
 
5pg/ml)
in the BAL fluid of NJ.1726 mice. Moreover, Northern
blot comparisons of endogenous pulmonary cytokine and
chemokine gene activity in (
 
 
 
/
 
 
 
) and transgenic animals
showed that IL-4, RANTES, MCP-3, and eotaxin re-
mained at low and/or nearly undetectable levels in the
lungs of NJ.1726 mice (data not shown).
 
IL-5 Induced Changes in Bone Marrow Cell Populations and
the Development of a Peripheral Eosinophilia.
 
The hematopoie-
tic consequences of IL-5 overexpression in the lung and
augmentation of blood serum levels are shown in Table 1.
NJ.1726 mice have white blood cell (WBC) counts that are
moderately elevated relative to (
 
 
 
/
 
 
 
) (approximately four-
fold),  exceeding 41,000 cells/mm
 
3
 
. This increase results
primarily from an expansion of peripheral eosinophils (2
versus 42%) although all other WBC types examined in-
creased in absolute number. NJ.1726 femoral marrow cel-
lularity, however, remained unchanged relative to (
 
 
 
/
 
 
 
)
mice. The lack of change associated with the total marrow
cell count masks a fundamental shift in cell composition.
Eosinophils increased by 
 
 
 
20-fold relative to (
 
 
 
/
 
 
 
) and ac-
counted for 50% of the transgenic marrow cells. In contrast,
there was a substantive decrease in erythroblasts (60% loss).
This decrease, however, did not effect peripheral red blood
cell counts as assayed by hematocrit (55.3 versus 54.3)
probably reflecting a shift in erythropoiesis from the mar-
Figure 2. Localization of IL-5 transcripts to the lung epithelium of NJ.1726 mice. An IL-5 antisense RNA probe was synthesized from an IL-5 cDNA
(a kind gift of T. Honjo) cloned into the plasmid vector pBluescript KS( ). No signal was detected when a sense probe was hybridized to adjacent sec-
tions (data not shown). TB, terminal bronchiole; AD, alveolar duct; AS, alveolar space; BALT, bronchus-associated lymphoid tissue. Bar, 25  m. 
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row to an extramedullary site (e.g., spleen, unpublished ob-
servations).
 
Airway Expression of IL-5 Results in Histopathologic Chang-
es in the Lung.
 
A systematic gross and microscopic survey
of adult tissues revealed that, except for mild splenomegaly,
the only pathologic manifestations of pulmonary IL-5 over-
expression were found in the lungs. The most prominent
abnormalities included expansion of bronchus-associated lym-
phoid tissue (BALT) (33) and the infiltration of peribron-
chial spaces by leukocytes. The severity of these changes
varied greatly and is shown in comparison to (
 
 
 
/
 
 
 
) in the
hematoxylin/eosin (H/E) sections of Fig. 3, 
 
a–c.
 
 BALT ag-
gregates (dominated by mononuclear cells) were sur-
rounded by a lymphoepithelium segregating them from the
airway lumen. All NJ.1726 animals examined exhibited these
pulmonary changes (
 
n
 
 
 
 
 
 11). The majority (54%) showed
increases in BALT within the range presented (Fig. 3, b and c).
For reasons that remain unclear,  27% of 3–8-mo-old ani-
mals displayed the extreme form of this pathology (Fig. 3
c). The accumulation of leukocytes was associated with the
expansion of the lymphoid tissue around nearly all the larger
airways. This expansion was often so great that it resulted
in the apparent closure or near occlusion of affected airways
(Fig. 3 c, arrows). The appearance of this extreme pheno-
type was random and did not segregate to specific cages of
mice or locations within the mouse colony, nor did it
shorten the life-span of transgenic animals. Fig. 3 d shows
bronchioles and the surrounding leukocytes at higher mag-
nification. In addition to epithelial hypertrophy, the lym-
phocytic infiltration was associated with perturbations of
the bronchial epithelium and thickening of the epithelial
submucosal region of some bronchioles.
The leukocyte infiltration associated with NJ.1726 lungs
resulted directly from the specific expression of IL-5 in the
lung epithelium. Fig. 3 e is a representative H/E section of
lung from an age-matched transgenic animal constitutively
expressing IL-5 from a T cell–specific promoter (transgenic
line NJ.1638 [22]). Serum IL-5 in these mice reaches as
high as 800 pg/ml; yet, as shown here, the animals do not
exhibit any significant lung pathology (i.e., an increase in
peribronchial leukocytes or an expansion of BALT).
Additional histological analyses of NJ.1726 lungs dem-
onstrated that other changes have also occurred as a con-
sequence of airway expression of IL-5. Lung sections stained
with alcian blue (pH 2.5) to detect weakly acidic sulphated
mucins showed relatively few epithelial goblet cells in ( / )
animals (Fig. 4 a). In contrast, NJ.1726 mice had an in-
crease in the number, distribution, and staining intensity of
goblet cells. These increases were evident in the epithelium
of large bronchi (Fig. 4 b) as well as smaller more distal
bronchioles (Fig. 4 c). Masson’s trichrome staining (Fig. 4,
d–f) demonstrated that the areas of expanded BALT in
NJ.1726 lungs are often accompanied by the deposition of
collagen (blue staining extracellular glycoprotein) and hy-
pertrophy of the bronchial epithelium. A higher magnifica-
tion view of the bronchiole and the surrounding BALT
showed that the epithelial hypertrophy involves both cili-
ated and mucus-secreting cells (Fig. 4 f, arrows). Interest-
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ingly, all of these additional histopathologic changes were
independent of the severity of the BALT expansion. Gob-
let cell hyperplasia, epithelial hypertrophy, and focal col-
lagen deposition were observed in nearly all NJ.1726 mice
and appear to be tightly linked to IL-5 airway expression.
Lung-specific IL-5 Expression Results in Eosinophil Accumu-
lation in the Peribronchial Spaces and Eosinophil Infiltration of
the Airway Lumen. The total cellularity and composition
of the parenchymal infiltrate was determined by analyses of
cells recovered from collagenase treatment of perfused lungs.
Figure 3. Histopathologic pulmonary changes accompany lung epithelial expression of IL-5. (a) Wild-type, (b–d) NJ.1726, and (e) a transgenic mouse
expressing IL-5 from T cells (line NJ.1638 [22]) were stained with hematoxylin and eosin before bright-field photomicroscopy. b and c are representative
photographs of the variation in phenotype found in NJ.1726 mice. The arrows in c indicate airways in an NJ.1726 mouse nearly occluded by the expan-
sion of peribronchial lymphoid tissue. The high magnification view of a BALT aggregate (d) shows in greater detail the additional histopathologies asso-
ciated with these regions. e demonstrates that although T cell–specific expression of IL-5 elevates serum levels to 400–800 pg/ml, no pulmonary changes
occurred, and thus the pathologies occurring in NJ.1726 mice are the result of lung-specific IL-5 expression. B, bronchiole; PV, pulmonary blood vessel;
AS, alveolar space; BALT, bronchus-associated lymphoid tissue. Bars: (a–c, e) 200  m; (d) 50  m.2149 Lee et al.
The resulting cell counts and differentials are displayed in
Fig. 5 A. The total cellular infiltrate of NJ.1726 lungs in-
creased fourfold relative to wild-type and was dominated
by eosinophils ( 50%). The fractional increase of eosino-
phils occurred with decreases in the percentages of all other
WBC types. However, if the increase in total lung paren-
chymal cells of NJ.1726 is taken into account, then the ab-
solute numbers of all leukocyte populations increased rela-
tive to wild-type. Thus, in addition to a 57-fold increase in
the numbers of parenchymal eosinophils, the absolute
numbers of NJ.1726 lung lymphocytes and monocytes/
macrophages actually increased relative to wild-type 1.8-
and 2.1-fold, respectively.
The presence of eosinophils infiltrating the peribronchial
spaces was confirmed by immunofluorescence using a poly-
clonal antisera against the eosinophil granule protein mMBP
Figure 4. Goblet cell hyperplasia, epithial hypertrophy, and collagen deposition are induced by airway expression of IL-5. (a–c) Alcian blue (pH 2.5)
staining of wild-type (a) and NJ.1726 lung sections showing a large bronchus (b) and a smaller more distal bronchiole (c). Intensely blue staining areas are
glycoprotein (mucin)-containing goblet cells. (d–e) Masson’s trichrome staining of paraffin sections derived from wild-type (d) and NJ.1726 (e and f)
lungs. The darkly blue staining extracellular material is collagen. The arrows in f indicate hypertrophy in the bronchial epithelium. AE, airway epithe-
lium; B, bronchiole; PV, pulmonary blood vessel; AS, alveolar space; BALT, bronchus-associated lymphoid tissue. Bars: (a–e) 50  m; (f) 25  m..2150 IL-5–induced Pulmonary Pathology
Figure 5. Cell differentials and eosinophil-specific immunofluorescence demonstrate a dramatic peribronchial infiltrate. (A) Collagenase-digested per-
fused lungs from NJ.1726 mice (n   4) and transgenic negative littermates (n   3) were dispersed to single cell suspensions prior to the assessment of lung
parenchymal cellularity. The total cell counts of lung parenchymal leukocytes are shown as the histograms on the left. The relative numbers of different
types of leukocytes (lung cell differentials) were determined from Wright’s stained cytocentrifuge preparations and are shown as the histograms on the
right. These data are expressed as the means ( SD) of the percentage of each cell type derived from differentials based on 200 cells. Mono, monocytes and
macrophages; Lym, lymphocytes; Eos, eosinophils; Neu, neutrophils; Mast, mast cells. (B) Parenchymal eosinophils were localized within the lung by im-
munofluorescence using an anti-mMBP polyclonal rabbit antiserum. Serial lung sections (4  m) were stained with H/E (1, 4, and 6), anti-mMBP serum
(2, 5, and 7), and prebleed serum (3) to visualize lung histology and eosinophil infiltration. These photographs represent serial tissue sections from a lung
of an NJ.1726 mouse (1–5) or a ( / ) control animal (6 and 7). B, bronchiole; PV, pulmonary blood vessel; AS, alveolar space; BALT, bronchus-asso-
ciated lymphoid tissue. Bars: 50  m.2151 Lee et al.
(Fig. 5 B). This polyclonal antisera was generated from rab-
bits immunized with purified mMBP isolated from mature
peripheral eosinophils (34). The specificity of the antisera
was determined by radioimmunoassay and differential bind-
ing to eosinophils present in cytospin preparations of WBC
(data not shown). Mature eosinophils were common in the
peribronchial spaces of NJ.1726 mice and distributed through-
out the lung parenchyma (Fig. 5 B, 1–3). Concentrated foci
of eosinophils surrounding areas of BALT were also com-
mon (Fig. 5 B,  4 and 5). The expanded peribronchial
lymph nodes and the respiratory epithelium were virtually
devoid of eosinophils. The immunofluorescence data also
demonstrated that extensive areas of extracellular major ba-
sic protein were not detectable, suggesting that the patho-
physiologic changes observed in NJ.1726 mice were not
the result of eosinophil degranulation and cationic protein
deposition.
Lung-specific IL-5 expression also resulted in the differ-
ential recruitment of eosinophils to the airway lumen. Fig. 6
compares the total cellularity and composition of leuko-
cytes found in the BAL fluid of ( / ), NJ.1726, and OVA
sensitized and challenged ( / ) mice. The total number
of BAL cells in NJ.1726 did not change appreciably relative
to ( / ) (1.06   105 versus 0.87   105 cells, respectively).
The absence of an increase in the number of leukocytes in
the BAL of transgenic animals is consistent with observa-
tions from asthmatic patients (35). Furthermore, this com-
parison also extends to changes induced in the composition
of cells recruited to the BAL. The percentage of BAL eosin-
ophils in NJ.1726 mice increased ( 1 versus 7%) to levels
similar to those observed in human asthmatic patient popu-
lations (35). This result was dramatically different from ob-
servations of BAL cells derived from OVA sensitized and
challenged ( / ) mice. The respiratory inflammation in-
Figure 6. Infiltration of the
airway lumen by eosinophils did
not occur as a consequence of
the pulmonary changes in
NJ.1726 mice. BAL cells derived
from the lungs of 7-mo-old
wild-type ( / ) (n    6),
NJ.1726 (n   3), and, for com-
parison, control ( / ) animals
sensitized (i.p.) and challenged
with aerosolized OVA (BAL cells
assessed 2 d after aerosol chal-
lenge) are displayed as histograms
showing total BAL cellularity
(left) and the relative numbers of
different types of leukocytes
(BAL differentials) determined
from Wright’s stained cytocen-
trifuge preparations (right). The
fractional compositions of each
cell type are expressed as per-
centages derived from differen-
tials of 200 cells. Data represent
mean values  SD.  M , mac-
rophages;  Lym, lymphocytes;
Eos, eosinophils; Neu, neutro-
phils; Mast, mast cells.
Figure 7. AHR in the absence of antigen sensitization and challenge
occurs only in lung-specific IL-5–expressing transgenic mice. Airway re-
sponsiveness of NJ.1726 mice (A) and transgenic mice expressing IL-5
from a T cell–specific promoter (B) was measured immediately after ex-
posure to aerosolized methacholine. In each case, measurements were
made relative to age matched (3–5 mo) transgenic negative littermates.
Mice were assessed on two occasions and the average for each animal was
obtained. Values reported are group means  SD (n   11). These data
were used to derive the effective dose200 ED200 levels (i.e., 50% maximal
response) shown in the histograms to the left. The ED200 for NJ.1726
transgenic mouse group was significantly different from the control wild-
type mice (*P  0.01).2152 IL-5–induced Pulmonary Pathology
duced in this mouse model resulted in a significant increase
(approximately sixfold) in total BAL cellularity that occurred
as a consequence of an increase in the number of eosino-
phils recruited to the airway lumen ( 60% of total BAL
cells) as well as smaller increases in neutrophil and lympho-
cyte numbers.
IL-5 Expression in the Lung Results in the Development of
AHR. AHR in response to a cholinergic agonist is a
physiologic perturbation characteristic of asthma and other
respiratory disorders. In an attempt to correlate the IL-5 in-
duced inflammatory changes in NJ.1726 mice to this re-
sponse, we measured airway responsiveness to methacho-
line challenge. NJ.1726 mice, or wild type animals, were
exposed to increasing concentrations of aerosolized metha-
choline and AHR was measured by whole-body plethys-
mography. Data from transgenic and control animals (n  
11 for each group) were collected as the means of duplicate
single-animal measurements and are displayed in graphical
form in the left panel of Fig. 7 A. The effective doses of
methacholine that achieved 50% maximal responsiveness
(ED200) are shown as histograms to the right of the primary
data. NJ.1726 mice had a lower threshold dose for metha-
choline-induced airflow obstruction compared with wild-
type controls. In addition, NJ.1726 mice also displayed AHR
to methacholine challenge in group mean dose-response data
or when the mean of individual NJ.1726 ED200 measure-
ments are compared to the control animals (69 versus 197 mg/
ml, respectively). Our AHR measurements showed surpris-
ingly little variation in response to increasing methacholine
concentration among the cohort of animals examined. We
also found little difference in the threshold dose for metha-
choline-induced airflow obstruction among the transgenic
animals suggesting that AHR to methacholine challenge is
independent of the varying severity of the BALT expansion
found in NJ.1726 mice. This increase in AHR was re-
stricted to lung-specific IL-5 expressing animals and was
not observed in transgenic mice (line NJ.1638, [22]) consti-
tutively expressing high levels of serum IL-5 (Fig. 7 B). The
lack of AHR in these mice suggests that aerosolized metha-
choline does not induce systemic perturbations of either
the upper or lower respiratory tracts in response to serum
IL-5 or elevated peripheral eosinophil numbers. The high
WBC count ( 400,000 cells/mm3;  60% eosinophils) and
the ubiquitous presence of elevated levels of tissue eosino-
phils in NJ.1638 mice (e.g., nasal passageways) are particu-
larly significant because they occur in the absence of exten-
sive lung histopathology. Thus, the AHR in mice expressing
IL-5 from the airway epithelium appears to correlate with
the observed lung histopathologies found in these animals
(i.e., lower respiratory tract changes) and not with potential
changes that may be induced by IL-5 in the upper respira-
tory tract.
Notably, the airway responsiveness displayed by NJ.1726
mice was achieved in the absence of an inflammatory stim-
ulus (e.g., aerosolized antigen challenge). In relative terms,
the increase in AHR observed in naive transgenic mice is
comparable to that observed in ovalbumin sensitized and
challenged C57BL/6J mouse models of asthma (threefold
versus three- to fivefold, respectively [our unpublished ob-
servations]).
Discussion
Lung-specific Expression of IL-5: Pulmonary Changes Resem-
bling Allergen-induced Respiratory Inflammation. Inflammatory
responses in the lung are mediated by cytokine and
chemokine expression, including IL-5, derived predomi-
nately from the airway leukocyte infiltrate (4). We have se-
lectively replicated IL-5 expression from the airway by ec-
topically expressing this cytokine in the lung epithelium.
Although the IL-5 expression in NJ.1726 mice is detectable
using an antibody-specific ELISA assay, it is not known
whether this ectopically produced IL-5 protein has full bio-
logical activities. However, since structure–function studies
of ectopically expressed IL-5 in COS cells demonstrated that
transfected cells were able to produce functional IL-5 (as-
sayed by proliferation of an IL-5–dependent cell line) (36),
it is likely that fully active cytokine can be produced by
most cell types.
The prominent changes observed in NJ.1726 mice were
an expansion of BALT, goblet cell hyperplasia, epithelial hy-
pertrophy, an increase in peribronchial eosinophils, and the
recruitment of eosinophils to the airway lumen. Areas of
BALT in the lung are composed mostly of B cells and have
been suggested as regions of antigen uptake (33, 37). In
NJ.1726 mice, these areas are dominated by mononuclear
cells (mostly lymphocytes) and thus the expansion of BALT
may be a consequence of IL-5 proliferative effects on exist-
ing B lymphocyte populations (22, 38). If IL-5 effector
functions rely in part on paracrine mechanisms, then the
specific effects associated with the cellularity surrounding
larger airways may be an indication of this regulatory loop.
The appearance of expanded regions of lymphoid tissue is
common to mouse models of respiratory disease (for exam-
ple see reference 9) and may reflect localized cytokine gene
expression. However, this is not a major feature of human
disease, perhaps highlighting underlying immunologic dif-
ferences between rodents and primates that are reflected in
physiologic differences in response to pulmonary inflamma-
tory stimuli. In addition to the varying effects on larger air-
way peribronchial lymph nodes, other histological pertur-
bations also occurred suggesting that chronic expression of
IL-5 at an elevated level leads to pathologic changes in the
lung. These perturbations (i.e., increased numbers of goblet
cells, deposition of collagen among the leukocyte aggregates,
and hypertrophy of the airway epithelium) occurred in
nearly all transgenic animals and are consistent characteris-
tics of several human inflammatory lung diseases (e.g.,
asthma [26, 39, 40] and bronchopulmonary aspergillosis [41])
that are associated with increased IL-5 levels in the lung.
The infiltration of the peribronchial interstitium and the
airway lumen by eosinophils in the absence of antigen sen-
sitization and challenge was a diagnostic phenotype of the
transgenic animals. Since allergic type I hypersensitivity (i.e.,
aerosolized OVA challenge) in wild-type mice induces a
large airway lumen infiltrate dominated by eosinophils, the2153 Lee et al.
lack of a large increase in BAL total cellularity in NJ.1726
animals suggests specific differences exist between these
models. It is likely that in addition to elevated levels of IL-5
expression, aerosolized OVA challenge also results in the
expression of other signals (e.g., chemokines) that are criti-
cal for the activation and subsequent migration of eosino-
phils from the peribronchial spaces.
Different TH2 Cytokines Elicit Distinct Pulmonary Effector
Functions: IL-4 versus IL-5. The ectopic expression in the
lung epithelium of the two dominant TH2 cytokines, IL-4
and IL-5, have now been reported. Expression of IL-4 us-
ing the rat CC10 promoter produces pathologic changes
leading to the recruitment of lymphocytes and both eosin–
ophils and neutrophils into the airway lumen (21). In addi-
tion, IL-4 expression elicited hypertrophy of the epithe-
lium of the larger airways and increased the baseline airway
resistance of transgenic lungs relative to wild-type controls.
Surprisingly, the data presented also showed that IL-4 ex-
pression in the lung had no demonstrable effect on AHR in
response to methacholine challenge.
Since the measured levels of IL-4 in the BAL fluid were
only 4% of the IL-5 levels found in NJ.1726 mice, it is dif-
ficult to compare, in absolute terms, the effects of IL-4 ver-
sus IL-5 airway expression. However, several qualitative con-
clusions are worth noting: (a) whereas the presence of IL-4
in the BAL of transgenic mice induced a leukocytic airway lu-
men infiltrate (fivefold relative to wild-type) that included
macrophages (44%) and approximately equal numbers (i.e.,
15–20%) of lymphocytes, eosinophils and neutrophils, ex-
pression of IL-5 at levels 23-fold higher did not alter total
BAL cell numbers and induced only an increase in BAL
eosinophils. (b) Overexpression of either IL-4 or IL-5 in
transgenic mice induced histopathologic pulmonary changes
(e.g., epithelial hypertrophy and increases in BALT). The
histopathologies reported here for IL-5 transgenic mice are
more pronounced than the observed IL-4 pathologies;
however, this difference may be a consequence of the rela-
tive levels of cytokine. (c) Unlike the IL-4 transgenic mice,
the expression of IL-5 in the airway lumen leads to AHR
in the absence of antigen sensitization and challenge. Al-
though AHR to methacholine challenge may also be a
consequence of the higher level of cytokine expression
found in NJ.1726 mice, this pathophysiologic response
does correlate with the higher degree of histopathology ob-
served in IL-5 transgenic mice.
IL-5 Is a Link to Signaling Cascades Leading to AHR.
AHR is a complex pathophysiologic response that has been
shown to occur as a consequence of several independent
pathways. The role of IL-5 gene expression, eosinophil ac-
cumulation in the lungs, and the development of AHR has
been controversial. In mouse models of respiratory inflam-
mation, many studies have linked IL-5 expression and the
recruitment of eosinophils to the lung (41, 42); however,
the correlation of IL-5 expression and AHR has been more
problematic.
The inability of IL-5–deficient mice to develop AHR and
airway eosinophilia after ovalbumin sensitization and chal-
lenge  suggested that IL-5 was required (17). Moreover,
ovalbumin sensitization and challenge of wild-type mice
treated with anti–IL-5 antibodies also resulted in the abro-
gation of the recruitment of eosinophils to the lung and the
development of AHR (43). In contrast, other studies with
anti–IL-5 antibodies showed that eosinophil airway infiltra-
tion can be significantly reduced without any effect on
AHR (11, 44). In the most recent study, Corry et. al. (11)
have reported that although treatment of mice with anti-
bodies to IL-4 mimics the responses of IL-4–deficient
mice, treatment with anti–IL-5 antibodies results in the
elimination of eosinophil airway infiltration but had no ef-
fect on AHR in response to ovalbumin sensitization. Several
explanations have been offered to resolve these differences
(e.g., differences in sensitization protocols [43] and inbred
mouse strain variation [45]); however, it is most likely that
the passive immunization protocols may have incompletely
neutralized endogenous IL-5. This conclusion is supported
by studies in ovalbumin sensitized and challenged guinea
pigs in which low levels of anti–IL-5 antibodies inhibited
eosinophil infiltration into the airways without affecting
AHR, whereas high levels of anti–IL-5 antibodies elimi-
nated both eosinophil recruitment and AHR (46). This ef-
fect, however, is more complex than cells within the lung
responding to elevated levels of serum IL-5. Transgenic an-
imals with high serum IL-5 levels derived from several
non-lung cell types display no pulmonary pathologies (see
Fig. 3 e; 22–24) and measurements of AHR in response to
methacholine challenge showed that these mice also do not
exhibit bronchial hyperreactivity in the absence of antigen
sensitization and challenge (see Fig. 7; 25, 47).
The data reported here show that unlike OVA-induced
models of respiratory inflammation, AHR in NJ.1726 mice
can be linked to changes in BAL cellularity comparable to
those observed in asthmatic patient populations. This phe-
nomenon occurs in the absence of antigen sensitization and
challenge and only in transgenic animals where the primary
source of IL-5 is the lung. AHR also occurred in all
NJ.1726 mice and did not parallel the large variation in
BALT expansion found in these animals. This observation
suggests that AHR is not linked to changes in BALT and
instead may correlate to one of the histopathologies that
occur in all transgenic mice (e.g., goblet cell hyperplasia,
epithelial hypertrophy, and focal collagen deposition). The
observations presented cannot eliminate the possibility of
IL-5–induced eosinophil effector functions mediated through
the large peribronchial infiltrate or the recruited BAL cells
as factors in the development of AHR; however, the in-
duction of this pathophysiologic response in NJ.1726 mice
shows that lung-specific IL-5 expression is a sufficient in-
flammatory signal to induce AHR, airway lumenal infiltra-
tion by eosinophils, and histopathologic pulmonary changes.
In this paradigm, ectopic lung-specific IL-5 expression re-
produces some but not necessarily all of the signals associ-
ated with asthmatic inflammation.
Although IL-5 expression in the lung leads to specific
pathophysiologic changes such as AHR, the absolute mag-
nitude of these changes are less than those observed in
many patients with asthma (48). This suggests either spe-2154 IL-5–induced Pulmonary Pathology
cies-specific pathophysiologic differences or the pathologies
found in patient populations result only in part because of
IL-5 effector functions and that the presence of other in-
flammatory signals (e.g., chemokine expression, IgE, or masts
cells), perhaps working synergistically with IL-5 (49–51),
lead to the augmentation of disease symptoms. The combi-
natorial effect of the pulmonary IL-5 expression found in
NJ.1726 mice and exposure to an extrinsic inflammatory
stimulus is not yet known. These experiments are of partic-
ular interest because of the potential to augment the ob-
served pathologies in IL-5 transgenic mice and reproduce
conditions seen in patient populations with severe respira-
tory disease.
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